Testing drug safety in healthy human subjects.

Testing drug safety in healthy human subjects.

• A. Phase 2 clinical trials
• B. NDA
• C. Phase 1 clinical trials
• D. Post-Marketing Surveillance

Answer: (C)

Testing safety in healthy human subjects is addressed in Phase 1 clinical trials. These early studies are designed to evaluate how the drug behaves in the body and whether it is safe at increasing doses, using a small number of volunteers who do not have the target disease. The main goals are safety, tolerability, pharmacokinetics (how the drug is absorbed, distributed, metabolized, and excreted), and pharmacodynamics (the drug’s effects on the body). Phase 1 often includes single ascending dose and multiple ascending dose designs with close monitoring of adverse events, vital signs, labs, ECGs, and PK data to establish a safe starting dose and a dosing range for later trials. In contrast, Phase 2 trials test efficacy and further assess safety in patients with the condition of interest and help refine dosing; an NDA is the regulatory filing to obtain approval to market the drug; and Post-Marketing Surveillance (Phase 4) monitors safety in the general population after approval.

Testing safety in healthy human subjects is addressed in Phase 1 clinical trials. These early studies are designed to evaluate how the drug behaves in the body and whether it is safe at increasing doses, using a small number of volunteers who do not have the target disease. The main goals are safety, tolerability, pharmacokinetics (how the drug is absorbed, distributed, metabolized, and excreted), and pharmacodynamics (the drug’s effects on the body). Phase 1 often includes single ascending dose and multiple ascending dose designs with close monitoring of adverse events, vital signs, labs, ECGs, and PK data to establish a safe starting dose and a dosing range for later trials.

In contrast, Phase 2 trials test efficacy and further assess safety in patients with the condition of interest and help refine dosing; an NDA is the regulatory filing to obtain approval to market the drug; and Post-Marketing Surveillance (Phase 4) monitors safety in the general population after approval.